6 results about "Vilanterol" patented technology

The application discloses a component for rapidly separating a vilanterol intermediate, which comprises an extractor, the inside of the extractor is provided with a shell, the top of the inside of the shell is provided with an extraction assembly for rotating extraction, a filter plate is arranged at the inlet of the extraction assembly at the bottom of the shell through a connecting rod, the bottom of the shell is provided with a cleaning assembly for cleaning the filter plate, the cleaning assembly comprises: a connecting seat arranged at the bottom of the inside of the shell; a cleaning brush arranged at the top of the connecting seat and in contact with the bottom of the filter plate; and a stirring piece arranged at the bottom of the shell and rotating the connecting seat to stir and mix two-phase liquid, the stirring piece is arranged at the bottom of the shell and rotates the connecting seat to stir and mix two-phase liquid, the precipitated particles are filtered through the filter plate, the cleaning brush is driven to rotate on the filter plate through the rotation of the stirring rod, thereby cleaning the stains attached to the filter plate, preventing the precipitates from accumulating at the rotating drum and affecting the extraction efficiency, and the rotation of the stirring rod enables the two-phase liquid entering the bottom of the shell to be rapidly mixed together.

The invention discloses an improved process for preparation of Vilanterol or a pharmaceutically acceptable salt thereof with good yields and high purity.

The invention belongs to the field of in-vivo quantitative drug concentration analysis, and particularly discloses an LC-MS / MS analysis method for determining the concentrations of fluticasone furoate, vilanterol and imequat in plasma. According to the method disclosed by the invention, the contents of fluticasone furoate, vilanterol and umepiride in the blood sample can be accurately and quantitatively detected at one time through specific sample treatment and chromatography-mass spectrometry conditions, the sensitivity is high, the detection limit is low, a novel method capable of being practically popularized and applied is provided for pharmacokinetic research of the three components, and the method has popularization and application values.

The invention relates to the field of compounds, in particular to application of a small molecule compound in preparation of a CXCR7 agonist. The invention provides an application of a small molecule compound or a pharmaceutically acceptable salt thereof in preparation of a CXCR7 agonist, and is characterized in that the small molecule compound comprises one or more of JMS-17-2, rupatadine, ibutamolam mesylate, asenapine, alverine and vilanterol. The small molecule compound can specifically activate an intracellular beta-arrest signal channel instead of being coupled with a G protein signal channel, so that the small molecule compound can be used as a novel CXCR7 agonist.

The invention provides a liquid pharmaceutical composition comprising: a) at least one long-acting muscarinic receptor antagonist (LAMA) selected from the group consisting of glycopyrronium bromide, ipratropium bromide, umiclidium bromide, and revefenacin; b) at least one long-acting adrenoceptor agonist (LABA) selected from the group consisting of formoterol fumarate, salmeterol xinofoate; alformoterol tartarate, and vilanterol trifenate; and c) at least one inhaled corticosteroid (ICS) selected from the group consisting of beclomethasone dipropionate, budesonide, ciclesonide, fluticasone furoate, and fluticasone propionate; and wherein the composition is in the form of a solution for aerosolization, as well as methods and devices for use of the composition.